Barreleye is advancing the science of ultrasound by extracting far more diagnostic information from the raw radio-frequency (RF) signals that conventional scanners discard. Founded in 2021 by Professor Hyunmin Bae, dean of the KAIST Startup Institute and a faculty member in the School of Electrical Engineering, the company applies deep learning to RF-based quantitative ultrasound analysis to detect microstructural changes within human organs at high resolution. The aim is to move ultrasound from a primarily qualitative, operator-dependent modality toward objective, quantitative measurement that supports earlier and more consistent diagnosis.
The company's technology has broad clinical reach because ultrasound is inexpensive, radiation-free, and widely available. Barreleye is expanding its applications across breast cancer, thyroid disorders, liver diseases, and cardiovascular conditions, using its quantitative tissue-characterization approach to surface signals that are difficult for the human eye to assess from a standard B-mode image. By quantifying tissue properties, the platform can help clinicians distinguish benign from suspicious findings and track disease progression over time.
Barreleye is not building in isolation. The company conducts joint research with major hospitals in Korea and abroad, as well as with global medical device manufacturers, positioning its software to be embedded in or paired with existing ultrasound systems rather than requiring entirely new hardware. This partnership-driven strategy is well suited to a diagnostics market where validation with clinical institutions and integration with established imaging vendors are critical to adoption.
In November 2025, Barreleye announced approximately $10 million (about KRW 14 billion) in strategic Series A funding. Investors include KAIC TO Ventures, TBIC KAIST, the Tech Incubator Program for Startup, and Mirae Science and Technology, with earlier backing from Mirae Science & Technology Holdings and K2 Ventures. The capital supports continued clinical validation and commercialization of its RF-based quantitative ultrasound AI across its target indications.